Adds proprietary CAR sequence IP to Liberate’s selective in vivo delivery platform, strengthening the foundation of its emerging CAR-M therapeutic class Liberate Bio, Inc., a biotechnology company ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results